Cipla has received final US FDA approval for its Nilotinib Capsules (50 mg, 150 mg, 200 mg) for the treatment of Philadelphia ...

In a press release issued after market hours on February 20, Cipla announced that it has received approval for Nilotinib ...

Cipla announced that it has received final approval from the United States Food and Drug Administration (USFDA) for the new drug application (NDA) submitted for 'Nilotinib Capsules 50, 150 and 200 mg' ...

Nilotinib is an FDA approved drug used for the treatment of Philadelphia Chromosome Positive CML, which is a cancer of blood ...

Mumbai: Pharma major, Cipla, has received final approval from the United States Food and Drug Administration (USFDA) for the New Drug Application (‘NDA’) submitted for ‘Nilotinib Capsules 50, ...

Nilotinib (Tasigna®) is a highly potent and selective inhibitor of breakpoint cluster region (BCR)–V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), which was rationally designed ...

The BCR/ABL1 inhibitor Nilotinib is increasingly used to treat patients with chronic myeloid leukemia (CML). Although otherwise well-tolerated, Nilotinib has been associated with the occurrence of ...

Now a study from the GIMEMA CML Working Party has shown that nilotinib is safe and effective in patients with early-stage chronic-phase Ph+ CML. The results of this study support the role for this ...

A twice-daily tablet regularly used by the NHS could slow or even reverse certain forms of incurable dementia, a study has claimed. Nilotinib, a blood cancer medicine, was previously shown to ...

Mumbai: Cipla, an Indian multinational pharmaceutical company, has announced that the United States Food and Drugs ...